Introduction
Major depressive disorder (MDD) is a debilitating illness that affects approximately 350 million people worldwide.
1 There is accumulating evidence to support that the pathophysiol ogy of MDD involves multiple overlapping biological sys tems, the contributions of which may vary across individ uals. 2 In pursuit of more effective treatments at the individual level, there is thus a critical need to objectively identify bio markers of disease and treatment response. 3 Electroconvul sive therapy (ECT) is a rapidly acting and highly effective treatment for relieving severe depression in patients for whom standard pharmacological interventions have failed. 4 Despite impressive remission rates for ECT, with estimates ranging from 75% to 90%, 4, 5 there are potential cognitive side effects. Further, similar to other antidepressants, there is a lack of knowledge and consensus regarding the mechanism of antidepressant action. 6 Cumulative evidence describes depression as a brain net work disorder likely driven by abnormalities in corticolimbic circuits, including hippocampal and amygdalar regions and the dorsal (dACC) and subgenual (sgACC) anterior cingulate cortex and connected prefrontal cortex (PFC). [7] [8] [9] For example, structural alterations in the PFC, particularly the ACC, and in the hippocampus are consistently observed in patients with major depression. [10] [11] [12] Similarly, alterations in white matter pathways connecting these regions have been reported. 7, 8, 13 suggest the dACC, sgACC and bilateral hippocampus play key roles in the pathophysiology of MDD.
Various neuroimaging techniques have been increasingly applied to better understand depression and treatment related neuroplasticity in implicated frontolimbic regions. Proton magnetic resonance spectroscopy ( 1 HMRS) is a non invasive imaging technique that can identify neurochemical signals in brain tissue, such as glutamine/glutamate (Glx), Nacetylaspartate (NAA), phosphocreatinecreatine (Cre), choline and cholinecontaining compounds (Cho). 20 As such, 1 HMRS offers a unique opportunity for probing neurochem ical correlates and predictors of treatment response. Though not an extensive literature, several prior 1 HMRS studies have addressed links between altered neurometabolite concentra tions and depression. 20 Most consistently reported are obser vations of reduced glutamate levels in the ACC. 18, 21, 22 One study reported a reduced Glx:Cre ratio within the hippocam pus in unmedicated patients with unipolar MDD. 23 Studies exploring differences in NAA indicate reductions in the NAA:Cr ratio for the thalamus 24 and reduced NAA for the caudate, 25 yet no differences have been reported previously in the ACC, PFC, amygdala or hippocampus. 20 At least 1 re port shows elevated Cho in the putamen. 25 Early evidence suggests that ECT modulates altered brain chemistry in patients with MDD. For example, compatible with 2 earlier reports, 21, 22 our group has shown an increase, indicating normalization toward control values, of glutamate levels within the ACC in patients with MDD after 6 ECT ses sions. 18 Though most investigations of hippocampal NAA changes with ECT have not found differences, 26 at least 1 study has reported ECTrelated increases. 27 Another study reported a significant increase in hippocampal Cho levels after ECT in depressed individuals. 26 Despite some prior research, owing to small sample sizes and a focus on mostly single and varied anatomic regions, it remains unclear whether neurochemical markers are associ ated with and/or predict antidepressant response in regions that form components of both cortical and subcortical limbic pathways, which play pivotal roles in mood regulation and emotion. For metabolites showing treatment effects, it is also unclear whether signal changes are a consequence of the brief seizures elicited by ECT or whether they are more closely tied to the neurobiology underlying improvements in clinical symptoms. Furthermore, the question of whether neuro chemical profiles are predictive of clinical response has been mostly unexplored. To address the questions above, we sought to examine 1 HMRS-derived changes in neurochemis try underlying ECT treatment and ECTrelated clinical re sponse and to establish whether metabolite levels measured before ECT predict subsequent treatment outcome. We exam ined patients with MDD before, during and after ECT and compared them crosssectionally with demographically simi lar nondepressed controls. Controls were assessed twice to estimate normative values and variance. Based on the exist ing literature, we hypothesized that ECT would be associated with a normalization of Glx (change in the direction of con trols) in the ACC and that diseaserelated changes in NAA, Cho and Cre would also vary with ECT response. To our knowledge, this is the largest and most comprehensive study to date to address the links between 1 HMRS markers and rapid response to ECT in patients with MDD in both dorsal and ventral limbic pathways simultaneously.
Methods

Participants
We recruited patients with unipolar or bipolar depression who were experiencing a major depressive episode and who were scheduled to receive ECT at the University of Califor nia, Los Angeles (UCLA) Resnick Neuropsychiatric Hospital. Diagnosis was determined by a boardcertified psychiatrist (R.E.) following DSMIVRevised criteria and confirmed using the MiniInternational Neuropsychiatric Interview (M.I.N.I.). To be included, patients had to have experienced 2 or more earlier major depressive episodes and failed to respond to at least 2 prior medication trials. We excluded pa tients with separately diagnosed comorbid psychiatric disor ders, including schizophrenia, schizoaffective disorders, posttraumatic stress disorder, bipolar mania, attention deficit/hyperactivity disorder and dissociative disorders, and those with primary anxiety disorders. Other exclusion criteria were dementia, firstepisode depression, illness onset after age 50 years, depression related to serious medical ill ness, or any neuromodulation treatment (e.g., vagal nerve stimulation, repetitive transcranial magnetic stimulation) within 6 months of the ECT treatment index series. All pa tients were tapered off psychotropic medications, including antidepressants and benzodiazepines, over a period of 48-72 hours before enrolment and ECT treatment.
Patients were scanned and administered the Hamilton Rating Scale for Depression (HAMD17) at 3 time points: baseline (T1; occurring within the 24 hours preceding their first ECT session), first followup (T2; occurring between the second and third ECT treatment sessions) and second follow up (T3; occurring within 1 week of completing the ECT treat ment index, about 4 wk after the first treatment).
We used advertisements to recruit controls matched for age and sex from the same geographical area as patients. Controls were administered the M.I.N.I. to exclude those with a history of depression, other psychiatric or medical illness and/or a history of antidepressant use. Controls were scanned at 2 time points: baseline (C1) and followup (C2; occurring approxi mately 4 wk after the initial scan).
Exclusion criteria for all participants were history of alco hol or substance abuse within the 6 months preceding the study and/or substance dependence within the 12 months preceding the study, any neurologic disorder and contraindi cation to MRI scanning. All participants provided written in formed consent, and the UCLA Institutional Review Board approved our study protocol.
ECT treatment
During the index series, ECT (5000Q MECTA Corp.) was ad ministered 3 times a week using a standard protocol for J Psychiatry Neurosci 2017;42(1) anesthesia (1 mg/kg of methohexital) and paralysis (1 mg/ kg of succinylcholine). Administration of ECT followed the seizure threshold (ST) titration method, where after establish ing the ST, treatments were delivered at 5 × ST for right uni lateral (RUL) d'Elia lead placement using an ultrabrief pulse width (0.3 ms) and at 1.5 × ST for bilateral placement using a brief pulse width (0.5 ms).
Clinical measures
The HAMD17 28 and MontgomeryÅsberg Depression Rating Scale (MADRS) 29 were administered at the same time points as brain scanning. Because these scales are highly correlated, HAMD17 ratings were chosen as the primary measure of clinical response and used to determine associations with 1 HMRS markers.
Imaging protocol
Singlevoxel point resolved spectroscopy (PRESS) sequences were acquired using a Siemens 3 T Allegra system (repetition time [TR] 2200 ms, echo time [TE] 30 ms, spectral width 2000 Hz, 1024 samples) with and without water suppression (128/1 averages). We used a volumetric navigator to correct for motion and B0 inhomogeneities in real time. 30 High resolution motioncorrected multiecho MPRAGE images Table 1 shows the mean full width at half maximum (FWHM) and signaltonoise ratios estimated for each voxel.
Data preprocessing
To improve the signaltonoise ratio, we first used a GaussSeidel iterative update scheme to denoise 1 HMRS signals from each voxel. 32 Waterreferenced metabolite concentra tions were then computed with LCModel software. For Glx, metabolite concentrations from data points with Cramer-Rao lower bounds equal to or exceeding 20% were excluded from analysis. For NAA, Cre and Cho, Cramer-Rao lower bounds equal to or exceeding 10% were excluded, as these metabo lites typically display lower fitting error values. For cerebro spinal fluid (CSF) correction, preprocessing included removal of nonbrain tissue from the T 1 data and field inhomogeneity correction using BrainSuite software. 33 Thereafter, voxels of interest were mapped to the T 1 space in which they were in itially prescribed. We used the FSL stats tool to compute voxel tissue composition (grey mater, white matter and CSF in each voxel). Finally, to control for potential differences in tissue compositions between participants and experimental groups, metabolite concentrations were corrected for the frac tion of CSF content in each voxel. 34 
Statistical analysis
For the metabolites of interest (Glx, NAA, Cho and Cre), sta tistical analyses addressed crosssectional differences at base line between patients and controls, longitudinal effects of ECT, correlations with clinical response using HAMD17 ratings, and baseline metabolite levels as predictors of treat ment outcome.
For the analysis of crosssectional differences at baseline, we used analyses of covariance to explore differences includ ing age and sex as covariates. For the analysis of longitudinal effects of ECT, we used the general linear mixed model (GLMM), as it produces unbiased parameter estimates when observations are missing at random. It therefore allowed the inclusion of all data points in spite of missing cell values as a result of exclusionary Cramer-Rao bounds or missing time points. The GLMM used an unstructured covariance matrix, and time point (T1, T2 and T3) was included as a continuous variable with random intercepts and slopes to account for withinsubject correlations. For metabolites showing signifi cant main effects of ECT, we then examined time points pair wise. The GLMM was also used to compare metabolite val ues across time points (C1 and C2) in controls to establish normative variance for repeated measures.
Focusing only on the metabolites showing significant lon gitudinal effects of ECT, the analysis of correlations with clin ical response used the general linear model (GLM) to analyze the difference scores between baseline and the end of the ECT index in order to establish associations between change in metabolite levels and change in HAMD ratings. The analy sis of baseline metabolite levels as predictors of treatment outcome used the GLM to address whether baseline metabo lite levels predicted overall clinical response (i.e., the differ ence in HAMD ratings between T1 and T3). In contrast to the GLMMs, which included all available data points, only par ticipants completing each of the 3 time points for whom dif ference scores could be computed were included in our analy ses of correlations with clinical response and baseline metabolite levels as predictors of treatment outcome.
Followup analyses compared patients' T3 measures to controls' T1 measures to establish whether metabolites show ing ECT effects in patients normalize or diverge from control values over the course of treatment.
Finally, we performed post hoc analyses to test for poten tial interactions between patients with unipolar or bipolar de pression as well as for the effects of lead placement (defined as the percentage of ECT sessions including RUL) for those measures showing significant ECT effects. Because lead placement was clinically determined and not manipulated in this study, effects of lead placement were examined while controlling for baseline HAMD ratings.
Because some early evidence, including our own work, suggest that ECT elicits changes in 1 HMRS signals of Glx, NAA, Cho and Cre, 18,20,22 we set a 2tailed α level of 0.05 as the significance threshold to determine main effects of ECT. To reduce potential type 1 error, only metabolites showing significant main effects of ECT were subsequently examined for effects of joint longitudinal change with mood ratings and predictive effects.
Results
Demographic and clinical variables
Fifty patients (43 with unipolar, 7 with bipolar depression; 23 men, 27 women) and 33 controls (14 men, 19 women) matched for age and sex participated in the study. Figure 2 de scribes the flow of participants through the study and scanning sessions, and the demographic and clinical characteristics of participants are shown in Table 2 
Cross-sectional effects of diagnosis
Prior to ECT, patients displayed reduced left hippocampus NAA (F 1,67 = 11.38, p = 0.001) and elevated left hippocampus Glx (F 1,63 = 4.03, p = 0.049) compared with controls. In contrast, for the sgACC, Glx levels were decreased in patients relative to con trols at baseline (F 1,53 = 5.35, p = 0.025; Fig. 3 ). Means for each metabolite by group and time point are provided in Table 3 .
Longitudinal effects of ECT
The GLMM analysis showed main effects of ECT in the dACC, where patients exhibited decreased NAA ( Table 3 ).
Associations between ECT-related clinical response and metabolite concentrations
Correlations between changes in metabolite concentrations and HAMD scores indicated decreases in Glx in the left hip pocampus (F 1,29 = 4.898, p = 0.035) and increases in Glx in the 
Predictors of treatment outcome
Higher baseline metabolite levels of NAA in the dACC (F 1,27 = 4.22, p = 0.029) predicted greater changes in HAMD scores between T1 and T3 (Fig. 5) .
Follow-up analyses
Followup analyses comparing T3 metabolite values in pa tients with T1 metabolite values in controls (to explore pres ence or absence of normalization, i.e., changes in the direc tion of controls) showed a significant difference for NAA ( 
Effects of electrode placement and diagnostic group
No interactions were observed for lead placement or diagno sis of unipolar or bipolar depression (all p > 0.05) for metab olites showing significant longitudinal effects of ECT.
Discussion
Several models with varying degrees of clinical and preclin ical evidence, most commonly the neurotransmitter, neuro endocrine, anticonvulsant and neurotrophic models, are pro posed to explain the rapid antidepressant effects of ECT. 6, 35 To clarify the underlying mechanisms, the current investiga tion sought to identify the effects of ECT on 1 HMRS markers of brain chemistry and the correlates and predictors of thera peutic response. For this purpose we used singlevoxel 1 HMRS, which is typically associated with a higher signal tonoise ratio than multivoxel sampling, to determine changes in metabolites in the dACC and sgACC and in the left and right hippocampus, which are regions repeatedly im plicated in MDD and its treatment. [10] [11] [12] [14] [15] [16] Overall, our find ings demonstrate that ECT elicits robust but varied effects on neurochemistry within these components of frontolimbic net works. Specifically, results showed decreased NAA and in creased Cre in the dACC, increased Glx and Cre in the sgACC, and decreased right hippocampal NAA and left hip pocampal Glx with ECT in patients, whereas all metabolite levels remained stable across time in controls. At baseline, patients differed from controls for Glx in the sgACC and left hippocampus and for NAA in the left hippocampus. Baseline NAA levels in the dACC were shown to predict ECTrelated clinical response in patients. The potential mechanisms underlying change in each neurometabolite in association with ECT in the context of depressionrelated functional cir cuitry are discussed in the sections that follow.
Glutamate/glutamine
The current findings extend previous observations to show disruptions in Glx in patients with MDD and modulation of Glx levels with ECT, which vary by region. Specifically, Glx increased in the sgACC and decreased in the left hippocam pus with ECT, and these changes were associated with im provements in mood. Earlier crosssectional 1 HMRS studies have reported deficits of Glx levels within the hippocam pus, 23 prefrontal cortex 36 and ACC, 21, 22 which point to altered glutamate function in patients with MDD. Observations that Nmethyldaspartate (NMDA) receptor antagonists, such as ketamine, can exhibit rapid antidepressant effects also sug gest a key role of glutamatergic neurotransmission in rapid antidepressant response. 37 The sgACC, which to our know ledge has not previously been examined in the context of ECT with 1 HMRS, is implicated in many studies of MDD using other neuroimaging modalities. Such investigations re port abnormal sgACC function/activity, 11 which appear to be modulated with antidepressant treatments, including sleep depravation and deep brain stimulation, [38] [39] [40] and these find ings are compatible with the present observations for ECT. Though not identified as significant in the present study, mean Glx levels in the dACC, like the sgACC, increased across treatment (p = 0.16; Table 3 ), and this finding is com patible with those of our prior report in an independent sam ple showing increases in dACC glutamate after 6 ECT ses sions as well as results from other earlier studies. 18, 22 Our observations of joint change in Glx in the sgACC and left hippocampus with ECTrelated clinical response support that variations in Glx contribute, at in least part, to symptom improvements. These findings are in line with the neurotransmitter theory of ECT, which posits that changes in monoaminergic as well as glutamatergic signalling act to re lieve depressive symptoms. 35 At the brain systems level, dif ferential effects for Glx in the sgACC and left hippocampus may reflect the frequently reported dissociations between dorsally mediated hyporeactive top-down and ventrally mediated hyperreactive bottom-up circuitry in patients with MDD. Specifically, many prior functional imaging studies suggest that hypoactivity in prefrontal cortical networks, to gether with elevated activity in ventral limbic structures, con tribute to the pathophysiology of MDD. [41] [42] [43] [44] Here, prefrontal cortical networks are implicated in cognitive control and mood regulation, while ventral networks are considered more closely linked with emotional expression and auto nomic responses to emotion; antidepressive treatment has been reported to target these same networks. 9, 45 The sgACC shares considerable connections with both cortical and sub cortical limbic circuitry. It maintains associations with the dACC (part of the dorsal network) via the cingulum, with the hippocampal formation via the precommisural fornix and parahippocmapal gyrus and with the midbrain and brain stem (part of the ventral network) via the medial forebrain bundle. Further, the sgACC is adjacent to the septal nuclei, which are reciprocally connected with the hypothalamus, amygdala, olfactory bulb, habenula, cingulate and thala mus. 46 Altered function of these structures in MDD, 7,24 which may include both increased and decreased glutamatergic in nervation, may account for variable symptom profiles in MDD and their amelioration by antidepressant treatments, including ECT. Because of its unique position in the brain, Mayberg and colleagues 39 first posited the sgACC serves as a conduit between prefrontal moodregulating regions and subcortical emotional response regions.
The decrease in hippocampal Glx toward normative values with ECT, which was different from the pattern observed in the ACC, could potentially reflect a blocking of the excito toxic and/or inflammatory effects of longterm exposure to cellular and environmental stressors affecting ventral limbic structures preferentially. Prior evidence supports that en hanced glutamate release occurs from exposure to stress and leads to decreased neurogenesis, abnormal dendritic mor phology and cell loss in the hippocampus. 37 Larger than nor mal concentrations of glutamate in ventral limbic structures, specifically in the hippocampus, may thus normalize with ECT to restore glutamatergic homeostasis and neuroprotec tive and neurotrophic pathways.
N-acetylaspartate
Study results showed decreased NAA in the left hippocam pus in patients before treatment relative to controls. At the same time, NAA was also shown to decrease in the dACC and right hippocampus with ECT. NAA is synthesized and stored primarily in neurons. That is, although intercompart mental cycling occurs between neurons and glia and changes in NAA have been associated with neurodegenerative white matter disease, because NAA is highly detectable within neur onal tissue, a change in NAA is generally considered a = control baseline; C2 = control follow-up; ECT = electroconvulsive therapy; HAMD-17 = Hamilton Rating Scale for Depression; MADRS = Montgomery-Åsberg Depression Rating Scale; QIDS-SR = Quick Inventory of Depressive Symptomatology -Self-Report; RUL = right unilateral lead placement; SD = standard deviation; T1 = patient baseline; T2 = after the second session of ECT; T3 = after the ECT index series. *Unless indicated otherwise. †Data missing for 1 patient. ‡Estimated using the modified Edinburgh Handedness Inventory, where a laterality quotient of < 0.7 defined nondextrals. Data missing for 1 control. §Data missing for 2 patients. ¶Response defined as > 50% improvement in HAMD-17 scores over the course of treatment. Remitters defined as patients with HAMD-17 scores < 7 at the end of ECT. **Significant effect between T1 and T2.
† †Significant effect between T2 and T3. ‡ ‡Significant effect between T1 and T3.
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marker of neuronal integrity. 47 Reports of hippocampal vol ume deficits in patients with MDD 48, 49 and decreased neuro genesis in animal models of depression 50 suggest that depres sion is linked with neural atrophy. Observations of reduced NAA in patients compared with controls at baseline fits with this hypothesis. However, changes in NAA may also reflect reversible changes in neural metabolism rather than more permanent changes in the number or density of neurons. For example, NAA has been shown to enhance mitochondrial energy production from glutamate and to play a role in neur onal osmoregulation and axon-glial signalling 51 Observed reductions in NAA may be considered to reflect secondary mechanisms compatible with the anticonvulsant theory of ECT that proposes ECT effects are linked to restor ative neural processes that occur in relation to seizure ther apy. However, ECTrelated changes in NAA may also be compatible with the neurotropic model of ECT. Adult neuro genesis has been shown to occur after both ECS and epileptic seizures in animals. 52, 53 Thus, decreases in NAA with ECT may point to changes in the ratio of mature to im mature neurons, which may reflect enhanced adult neuro genesis, as has been linked with MDD and treatment re sponse in a growing number of studies. 50 Notably, studies have also shown that many adultborn neurons within the hippocampal dentate gyrus integrate into preexisting limbic circuitry to ultimately acquire electrophysiological character istics of mature neurons. 54, 55 Therefore, reductions in NAA may signify prerequisite neural processes that precede and/ or are necessary to stimulate subsequent neurotropic events. Whether ECTrelated changes in NAA are linked to changes in cognition may help clarify whether the NAA effects de scribed here are beneficial.
Creatine
Creatine, which is considered a marker of energy metabo lism, 47 has been shown to increase in the dACC and sgACC with ECT. The changes that we observed in Cre in the dACC and sgACC may thus suggest a corresponding change in energy use within these brain regions, which may be considered part of the dorsal corticolimbic network. Here, it may be possible that the restorative processes that H-MRS resolved metabolite concentrations in patients scanned at baseline (T1), after the second electroconvulsive therapy (ECT) session (T2) and at the end of the ECT index series (T3) and in controls scanned at 2 time points (C1 and C2). The brackets and p values show significant differences between patients and controls at baseline, significant overall effects of ECT and significant differences between each of 2 time points examined pairwise in patients. Results from follow-up analyses to determine normalization of metabolite concentrations with ECT by comparing T3 and C1 values are not shown. AU = arbitrary units; Glx = glutamate/glutamine; NAA = N-acetylaspartate; SE = standard error. occur after ECT may lead to an increase in the energy re quirements in these regions and consequently to increases in Cre. Though variations in Cre appear more likely related to the physiologic rather than the therapeutic effects of ECT (i.e., since associations with change in mood ratings were not observed), it remains possible that such associations are present but occur via intermediary processes.
Limitations
1 HMRS affords the important opportunity to assay changes in neurochemistry linked with antidepressant response. However, owing to crowded and overlapping resonance frequencies, few 1 HMRS markers are derived from a single compound, rendering it difficult to dissociate some metabo lites, such as γaminobutyric acid (GABA), without special ized pulse sequences or highfield MRI. Consequently, GABA was not measured in this study. Though using a powerful withinsubjects research design, attrition in longi tudinal assessments served to reduce this advantage such that clinical heterogeneity may still contribute to findings. Here, it is possible that regional changes in 1 HMRS signals may be more sensitive to changes in particular clinical symptoms and/or behavioural outcomes, 56 which could be addressed in future studies. The exclusion of some data points because of field inhomogeneities, which occurred more frequently in regions closer to CSF and the cerebral cisterns, is also a limitation. Hence, smaller yet clinically meaningful effects may have remained undetected in the present investigation. For example, since only patients who completed all 3 time points were included for correlational analyses with mood ratings while all available data were used to examine ECT effects, correlational analyses may be more susceptible to increased typeII error, and more subtle associations between change in metabolite concentration and symptom ratings may have remained undetected. Our findings correlating neurometabolite changes to clinical out come were moderate. Further, it is also plausible that such associations are not linear and/or that other mechanisms, such as modulation by GABA or other neurotransmitter systems not measured here and/or different time lapses in the molecular pathways leading to clinical improvement, impact these associations. Though we attempted to mini mize potential typeI and typeII error, our findings may yet warrant replication in future studies. Although we ob served no interactions, it remains possible that the diagnosis of unipolar versus bipolar depression (14% of the sample) may have impacted our results. Importantly, in line with a new focus on reconceptualizing currently used diagnostic categories by creating a research framework that more accu rately represents neurobiological dysfunction in individual patients (i.e., according to National Institute of Mental Health [NIMH] Research Domain Criteria) 56 blind to categorical diag nosis, the primary objective the present study was to ad dress links with treatment response in patients experiencing a major depressive episode. However, further studies includ ing much larger and more evenly matched diagnostic groups may address potential differential effects between patients with unipolar and bipolar depression specifically. Finally, since the majority of patients received RUL ECT exclusively and bilateral lead placement was based on clinical factors, we were not able to adequately address differential effects of lead placement on the observed results. Future studies may address some of these potential limitations explicitly.
Conclusion
The heterogeneous symptom presentation and clinical course of MDD and the moderate success rate of standard antidepressant therapies underscore the need for biological markers to better inform more personalized treatment deci sions. Advancing this goal, the present study demonstrates that ECT elicits pronounced, but differential effects on brain chemistry in cortical and subcortical limbic circuits. Though associations with clinical response are modest, findings sup port that the normalization of Glx in the sgACC and hippo campus contributes to symptom improvements. Observa tions that baseline measures of NAA, a 1 HMRS marker that is typically considered a marker of neural integrity, distin guish subsequent response to ECT, suggesting a potential clinical application pending further replication. Cumula tively, these findings appear most compatible with a neuro transmitter model of ECT response but also align with fea tures of other models previously described to explain the mechanisms of ECT.
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